Catherine Lai, MD, MPH discusses a study presented at ASH Annual Meeting on time to treatment initiation in patients with acute myeloid leukemia. The study focused on patients receiving azacitidine and venetoclax, tracking whether time to treatment initiation affected overall survival. Lai recommended waiting for all molecular testing in clinically stable patients to be treated with a hypomethylating agent and venetoclax combination. She disclosed serving on an advisory board for Astellas, BMS, Daiichi, Genentech, and Servier, consulting for AbbVie and Rigel, and receiving research funding from BMS and Jazz.
Source link
Some patients can wait for acute myeloid leukemia to start
